Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies

Zhiqin Wang; Bowen Wu; Guangjun Nie; Jingyan Wei; Yiye Li

doi:10.1016/j.canlet.2023.216138

Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies

Zhiqin Wang, Bowen Wu, Guangjun Nie, Jingyan Wei, Yiye Li

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with insidious onset and early distal metastasis. Metabolic reprogramming, the autonomous changes in cellular bioenergetics driven by aberrant genetic events and crosstalk between cancer and non-cancer cells in the desmoplastic microenvironment, is pivotal for the rapid progression of PDAC. As an attractive therapeutic target, nucleoside metabolism is regulated by various anti-metabolic drugs for the clinical treatment of PDAC. Despite various challenges, such as poor drug delivery efficiency and off-target side effects, metabolic modification and intervention are emerging as promising strategies for PDAC therapy, enabled by the rapid development of nanotechnology-based drug delivery strategies. In this review, we discuss the metabolic characteristics of PDAC and highlight how the development of nanomedicine has boosted the development of new therapeutics for PDAC by modulating critical targets in metabolic reprogramming.

Original language	English (US)
Article number	216138
Pages (from-to)	216138
Journal	Cancer Letters
Volume	560
DOIs	https://doi.org/10.1016/j.canlet.2023.216138
State	Published - Apr 28 2023

Keywords

Drug delivery
Nanomedicine
Pancreatic ductal adenocarcinoma
Tumor metabolism
Energy Metabolism
Humans
Pancreatic Neoplasms/pathology
Tumor Microenvironment
Carcinoma, Pancreatic Ductal/pathology

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.canlet.2023.216138

Cite this

@article{fd21304b99a54d168a91bb45c1131c2f,

title = "Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with insidious onset and early distal metastasis. Metabolic reprogramming, the autonomous changes in cellular bioenergetics driven by aberrant genetic events and crosstalk between cancer and non-cancer cells in the desmoplastic microenvironment, is pivotal for the rapid progression of PDAC. As an attractive therapeutic target, nucleoside metabolism is regulated by various anti-metabolic drugs for the clinical treatment of PDAC. Despite various challenges, such as poor drug delivery efficiency and off-target side effects, metabolic modification and intervention are emerging as promising strategies for PDAC therapy, enabled by the rapid development of nanotechnology-based drug delivery strategies. In this review, we discuss the metabolic characteristics of PDAC and highlight how the development of nanomedicine has boosted the development of new therapeutics for PDAC by modulating critical targets in metabolic reprogramming.",

keywords = "Drug delivery, Nanomedicine, Pancreatic ductal adenocarcinoma, Tumor metabolism, Energy Metabolism, Humans, Pancreatic Neoplasms/pathology, Tumor Microenvironment, Carcinoma, Pancreatic Ductal/pathology",

author = "Zhiqin Wang and Bowen Wu and Guangjun Nie and Jingyan Wei and Yiye Li",

note = "Funding Information: This work was supported by the National Key Research and Development Program of China ( 2021YFA1201103 ), the Beijing Natural Science Foundation ( Z210017 ), the National Natural Science Foundation of China ( 31820103004 ) and the Key Area R&D Program of Guangdong Province ( 2020B0101020004 ). Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = apr,

day = "28",

doi = "10.1016/j.canlet.2023.216138",

language = "English (US)",

volume = "560",

pages = "216138",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies

AU - Wang, Zhiqin

AU - Wu, Bowen

AU - Nie, Guangjun

AU - Wei, Jingyan

AU - Li, Yiye

N1 - Funding Information: This work was supported by the National Key Research and Development Program of China ( 2021YFA1201103 ), the Beijing Natural Science Foundation ( Z210017 ), the National Natural Science Foundation of China ( 31820103004 ) and the Key Area R&D Program of Guangdong Province ( 2020B0101020004 ). Publisher Copyright: © 2023 Elsevier B.V.

PY - 2023/4/28

Y1 - 2023/4/28

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with insidious onset and early distal metastasis. Metabolic reprogramming, the autonomous changes in cellular bioenergetics driven by aberrant genetic events and crosstalk between cancer and non-cancer cells in the desmoplastic microenvironment, is pivotal for the rapid progression of PDAC. As an attractive therapeutic target, nucleoside metabolism is regulated by various anti-metabolic drugs for the clinical treatment of PDAC. Despite various challenges, such as poor drug delivery efficiency and off-target side effects, metabolic modification and intervention are emerging as promising strategies for PDAC therapy, enabled by the rapid development of nanotechnology-based drug delivery strategies. In this review, we discuss the metabolic characteristics of PDAC and highlight how the development of nanomedicine has boosted the development of new therapeutics for PDAC by modulating critical targets in metabolic reprogramming.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with insidious onset and early distal metastasis. Metabolic reprogramming, the autonomous changes in cellular bioenergetics driven by aberrant genetic events and crosstalk between cancer and non-cancer cells in the desmoplastic microenvironment, is pivotal for the rapid progression of PDAC. As an attractive therapeutic target, nucleoside metabolism is regulated by various anti-metabolic drugs for the clinical treatment of PDAC. Despite various challenges, such as poor drug delivery efficiency and off-target side effects, metabolic modification and intervention are emerging as promising strategies for PDAC therapy, enabled by the rapid development of nanotechnology-based drug delivery strategies. In this review, we discuss the metabolic characteristics of PDAC and highlight how the development of nanomedicine has boosted the development of new therapeutics for PDAC by modulating critical targets in metabolic reprogramming.

KW - Drug delivery

KW - Nanomedicine

KW - Pancreatic ductal adenocarcinoma

KW - Tumor metabolism

KW - Energy Metabolism

KW - Humans

KW - Pancreatic Neoplasms/pathology

KW - Tumor Microenvironment

KW - Carcinoma, Pancreatic Ductal/pathology

UR - http://www.scopus.com/inward/record.url?scp=85150785481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150785481&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2023.216138

DO - 10.1016/j.canlet.2023.216138

M3 - Review article

C2 - 36934836

AN - SCOPUS:85150785481

SN - 0304-3835

VL - 560

SP - 216138

JO - Cancer Letters

JF - Cancer Letters

M1 - 216138

ER -

Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this